First patients test promising new drug for aggressive blood cancers
NCT ID NCT05526313
Summary
This was a first-in-human study to test the safety and find the right dose of a new drug called Purinostat mesylate (PM). It involved 29 adults with advanced blood cancers, like lymphoma and leukemia, that had returned or stopped responding to standard treatments. The main goal was to see how much of the drug the body could safely handle and how it behaved in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.